Caseware UK (AP4) 2025.0.111 2025.0.111 2025-12-312025-12-312025-01-01falseservices to the medical industry00truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 06452785 2025-01-01 2025-12-31 06452785 2024-01-01 2024-12-31 06452785 2025-12-31 06452785 2024-12-31 06452785 c:Director1 2025-01-01 2025-12-31 06452785 d:PlantMachinery 2025-01-01 2025-12-31 06452785 d:PlantMachinery 2025-12-31 06452785 d:PlantMachinery 2024-12-31 06452785 d:PlantMachinery d:OwnedOrFreeholdAssets 2025-01-01 2025-12-31 06452785 d:CurrentFinancialInstruments 2025-12-31 06452785 d:CurrentFinancialInstruments 2024-12-31 06452785 d:CurrentFinancialInstruments d:WithinOneYear 2025-12-31 06452785 d:CurrentFinancialInstruments d:WithinOneYear 2024-12-31 06452785 d:ShareCapital 2025-12-31 06452785 d:ShareCapital 2024-12-31 06452785 d:RetainedEarningsAccumulatedLosses 2025-12-31 06452785 d:RetainedEarningsAccumulatedLosses 2024-12-31 06452785 c:OrdinaryShareClass1 2025-01-01 2025-12-31 06452785 c:OrdinaryShareClass1 2025-12-31 06452785 c:OrdinaryShareClass1 2024-12-31 06452785 c:FRS102 2025-01-01 2025-12-31 06452785 c:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 06452785 c:FullAccounts 2025-01-01 2025-12-31 06452785 c:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 06452785 d:AcceleratedTaxDepreciationDeferredTax 2025-12-31 06452785 d:AcceleratedTaxDepreciationDeferredTax 2024-12-31 06452785 2 2025-01-01 2025-12-31 06452785 e:PoundSterling 2025-01-01 2025-12-31 xbrli:shares iso4217:GBP xbrli:pure

Registered number: 06452785










MAGNA MEDICAL LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 DECEMBER 2025

 
MAGNA MEDICAL LIMITED
REGISTERED NUMBER: 06452785

STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2025

2025
2024
Note
£
£

Fixed assets
  

Tangible assets
 4 
206,377
165,647

  
206,377
165,647

Current assets
  

Debtors: amounts falling due within one year
 5 
186,570
52,771

Cash at bank and in hand
  
14,097
184,262

  
200,667
237,033

Creditors: amounts falling due within one year
 6 
(163,510)
(172,502)

Net current assets
  
 
 
37,157
 
 
64,531

Total assets less current liabilities
  
243,534
230,178

Provisions for liabilities
  

Deferred tax
 7 
(11,971)
(31,473)

  
 
 
(11,971)
 
 
(31,473)

Net assets
  
231,563
198,705


Capital and reserves
  

Called up share capital 
 8 
2
2

Profit and loss account
  
231,561
198,703

  
231,563
198,705


Page 1

 
MAGNA MEDICAL LIMITED
REGISTERED NUMBER: 06452785
    
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2025

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 22 June 2026.


W M van Rijn
Director

The notes on pages 3 to 8 form part of these financial statements.

Page 2

 
MAGNA MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1.Accounting policies

 
1.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The presentational currency of the Company is GBP.

The following principal accounting policies have been applied:

 
1.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
1.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
1.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

Page 3

 
MAGNA MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1.Accounting policies (continued)

 
1.5

Current and deferred taxation

The tax expense for the year comprises current and deferred tax. Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the reporting date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.


 
1.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Plant & machinery
-
15%
reducing balance

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
1.7

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Page 4

 
MAGNA MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

1.Accounting policies (continued)

 
1.8

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
1.9

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
1.10

Provisions for liabilities

Provisions are recognised when an event has taken place that gives rise to a legal or constructive obligation, a transfer of economic benefits is probable and a reliable estimate can be made.

Provisions are measured as the best estimate of the amount required to settle the obligation, taking into account the related risks and uncertainties.
 
Increases in provisions are generally charged as an expense to profit or loss.


2.


General information

Magna Medical Limited is a private company, limited by shares and incorporated in Wales.

Its registered number is: 06452785

The address of its Registered office is: 
Unit 5
Chase Industrial Estate
Ross-On-Wye
Herefordshire
HR9 5WA


3.


Employees

The Company has no employees other than the directors, who did not receive any remuneration (2024 - £NIL).

Page 5

 
MAGNA MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

4.


Tangible fixed assets


Plant & machinery

£



Cost or valuation


At 1 January 2025
206,805


Additions
77,150



At 31 December 2025

283,955



Depreciation


At 1 January 2025
41,158


Charge for the year on owned assets
36,420



At 31 December 2025

77,578



Net book value



At 31 December 2025
206,377



At 31 December 2024
165,647

Page 6

 
MAGNA MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

5.


Debtors

2025
2024
£
£


Amounts owed by related parties
159,026
16,582

Other debtors
27,371
36,024

Prepayments and accrued income
173
165

186,570
52,771



6.


Creditors: Amounts falling due within one year

2025
2024
£
£

Trade creditors
60,184
74,627

Amounts owed to related parties
100,093
94,743

Other creditors
783
782

Accruals and deferred income
2,450
2,350

163,510
172,502



7.


Deferred taxation




2025


£






At beginning of year
(31,473)


Charged to profit or loss
19,502



At end of year
(11,971)

The provision for deferred taxation is made up as follows:

2025
2024
£
£


Accelerated capital allowances
(11,971)
(31,473)

(11,971)
(31,473)

Page 7

 
MAGNA MEDICAL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025

8.


Share capital

2025
2024
£
£
Allotted, called up and fully paid



2 (2024 - 2) Ordinary shares of £1.00 each
2
2



9.


Controlling party

The controlling party of the company is Leyden Holding BV, a company registered in the Netherlands. The ultimate controlling parties are W M van Rijn and M Helthuis-Jollie, by virtue of their shareholdings in Leyden Pharmaceutical BV.

 
Page 8